MedPath

Comparison of DPP4 inhibitors versus luseogliflozin, a SGLT2 inhibitor using cotinuous glucose monitoring (CGM)

Not Applicable
Conditions
type 2 diabetes
Registration Number
JPRN-UMIN000014333
Lead Sponsor
Ichinomiyanishi hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

liver or renal dysfunction

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
CGM(BS average, SD, MAGE, M-value, AUC)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath